NEW Phase C dossier — authored 2026-05-15 for shard-5-obped-id wave 7. Covers neonatal hyperbilirubinemia + kernicterus prevention — the most common condition requiring evaluation and treatment in the newborn period (~ 60% term, ~ 80% preterm clinically visible jaundice; ~ 5-10% pathologic above phototherapy threshold). Kemper AAP 2022 (PMID 35927462) is the current authoritative standard, substantially revised from the 2004 CPG. Seed manifest authored 2026-05-25 at prisma/seed/manifests/peds.hyperbilirubinemia-neonatal.v1.ts (seed-manifest exemplar pattern, mirroring ob.amniotic-fluid-embolism.v1 via defineBatch23ScaffoldManifest; specialty_pack pediatrics; sourceWorkupIds [neonatal_hyperbilirubinemia]; evidenceIds [ev_neonatal_hyperbilirubinemia_guideline_review_required]). Terminology anchors projected 1:1 from this dossier terminology block — no new SNOMED/ICD-10/LOINC codes invented; rxnorm_codes intentionally empty because the regimen is non_pharm/procedural (phototherapy, exchange transfusion, enteral feeds, IV crystalloid) and IVIG is brand-specific with no single RxCUI. The manifest pointer now resolves; status promoted PLANNED → INTEGRATED. Refined Phase-C-wave-7 pattern: 3-file new-dossier batch (TS + brief + research bundle) WITHOUT touching _registry.ts — registration will be picked up in a wave-roll-up commit (parallel-agent staging conflict avoidance per shard refined pattern). AAP 2022 key revisions vs 2004: (1) higher phototherapy thresholds (mean ~ 2 mg/dL higher) reflecting evidence brief mild-moderate hyperbilirubinemia is generally well-tolerated; (2) NEW escalation-of-care concept — TSB within 2 mg/dL of exchange threshold triggers admission to intensive-phototherapy / exchange-capable setting + IVIG (if isoimmune) + exchange-team activation; (3) universal G6PD testing in ALL infants requiring phototherapy (broader than 2004 history-based); (4) universal pre-discharge bilirubin screening + Bhutani 1999 nomogram percentile zone; (5) TcB validated as screening tool until > 12 mg/dL or post-phototherapy (then TSB required). Distinct from id.neonatal-sepsis.early-late.v1 (parent sepsis context; bidirectional routing with carryover of CBC, blood culture, current empiric regimen, gestational age, hours of age, TSB, DAT, G6PD, neurologic exam). This engine owns AAP 2022 threshold-based phototherapy + exchange pathway + kernicterus prevention; neonatal-sepsis owns the parent sepsis context. CRITICAL safety: AVOID ceftriaxone in hyperbilirubinemic neonate (bilirubin displacement from albumin); use cefotaxime if cephalosporin needed. Cross-reference id.hsv-neonatal.core.v1 (rare hepatic-HSV cause of conjugated hyperbilirubinemia with hepatitis features) — only routes if conjugated component emerges with maternal HSV / hepatitis features. Phenotype matrix (6-axis GA × hours-of-age × peak-TSB-band × risk-factors × treatment-response × neuro-findings — 756 cells collapsed to 10 anchor combinations) encoded indirectly via regimen_axes.hyperbilirubinemia_by_aap_2022_threshold_zone + severity_triggers (10 phenotype-specific triggers) + setting playbooks (icu = NICU/PICU / inpatient = newborn nursery + mother-baby + peds floor / outpatient = pre-discharge screening + outpatient peds + home phototherapy). First-class TS phenotype field is schema-blocked. Severity triggers (10 per binding): acute_bilirubin_encephalopathy_signs (life_threatening — Watchko & Tiribelli NEJM 2013; emergent exchange + intensive phototherapy + ICU + neuro consult; reversible if caught early), bilirubin_above_exchange_threshold_at_aap_2022 (life_threatening — emergent exchange + intensive phototherapy + hematology + IVIG if isoimmune), isoimmune_hemolytic_disease_rh_or_abo (severe — DAT positive + rising bilirubin → IVIG 0.5-1 g/kg + intensive phototherapy + close monitoring; exchange if continued rise), g6pd_deficiency_at_phototherapy (severe — AAP 2022 universal G6PD testing in all infants requiring phototherapy; treat aggressively; consider IVIG; avoid offending meds), preterm_lower_threshold_curves (severe — AAP 2022 explicitly excludes < 35 wk; case-by-case + hematology), inadequate_feeding_dehydration_with_hyperbili (severe — > 10% weight loss + low urine output → supplement + lactation consult + serum sodium check), discharge_pre_aap_safety_check_at_24_48h (mild — universal pre-discharge bilirubin + Bhutani-zone follow-up), home_phototherapy_failure_or_progression (severe — admission for intensive phototherapy + hemolysis workup + sepsis exclusion), late_preterm_higher_risk_for_progression (severe — late preterm 35-36 wk + exclusive BF + early discharge → closer follow-up), parental_education_kernicterus_prevention (mild — universal counseling on jaundice warning signs + when to seek evaluation). Bayesian linkage (per §5.5.2): pre-test priors documented in _research-bundles/peds.hyperbilirubinemia-neonatal.v1.md — clinically visible jaundice ~ 60% term + ~ 80% preterm; pathologic above phototherapy ~ 5-10%; exchange-level ~ 0.1-0.5%; kernicterus ~ 1 in 50-100K live births (preventable). Key LRs: TcB > 12 mg/dL mandates TSB; pre-discharge TSB > 95th percentile Bhutani → LR+ ~ 5-10 for follow-up phototherapy need; DAT-positive → LR+ ~ 10-15 isoimmune; G6PD-positive at phototherapy → LR+ ~ 5-10 for escalation; ABE neurologic signs → LR+ very high; cephalohematoma → LR+ ~ 3-5 for delayed peak; exclusive BF + > 10% weight loss + low UOP → LR+ ~ 4-8 for inadequate-intake-driven hyperbili. Decision thresholds: T_treat_phototherapy at or above AAP 2022 Figure 2; T_treat_exchange at or above AAP 2022 Figure 3 OR ABE; T_escalate within 2 mg/dL of exchange; T_treat_IVIG isoimmune + rising bilirubin or near exchange; T_admit_from_home_phototherapy rising despite home or not falling at expected rate. Cross-dossier routing: id.neonatal-sepsis.early-late.v1 (bidirectional carryover for sepsis cases), id.hsv-neonatal.core.v1 (rare conjugated component with hepatitis), out-of-engine peds-GI/hepatology (conjugated component ≥ 20% or ≥ 2 mg/dL direct → biliary atresia rule-out by 4 wk — Kasai outcomes time-sensitive). ROS/DDx LR seed data NOT touched (cross-cutting; not in shard scope). Settings (4 conceptual; 3 in DossierSetting vocabulary): prehospital / home (parental recognition + home phototherapy in selected low-risk; first-class "prehospital" DossierSetting value is schema-blocked, encoded implicitly via flow.entry_points + outpatient playbook drug_actions[home phototherapy]), NICU/PICU = "icu" in dossier-setting vocabulary (escalation-of-care zone + ABE + exchange-transfusion preparation + post-exchange monitoring + intensive phototherapy + IVIG), inpatient = newborn nursery + mother-baby + peds floor (standard phototherapy + serial TSB monitoring + lactation support + parental education), outpatient = pre-discharge screening + outpatient peds 24-48h follow-up + home phototherapy + long-term G6PD-trigger counseling + neurodev screening for at-risk. Drug + procedural guidance grounded in Kemper AAP 2022 + Watchko & Tiribelli NEJM 2013 + Maisels CMAJ 2015 + Cochrane IVIG reviews + standard exchange-transfusion procedure literature. Pharmacologic agents this engine: IVIG (brand-specific RxCUIs; not a single RxCUI; RxNav lookup deferred to next research loop), supplemental enteral feeds, IV crystalloid maintenance / resuscitation. Procedural: standard phototherapy (8-10 µW/cm²/nm at 460-490 nm), intensive phototherapy (≥ 30 µW/cm²/nm with multiple light banks), double-volume exchange transfusion (160 mL/kg via UVC with irradiated CMV-negative < 7 d old blood). CRITICAL safety carryover from sibling neonatal-sepsis dossier: AVOID ceftriaxone < 28 d (bilirubin displacement from albumin + calcium-IVF incompatibility); cefotaxime preferred; AVOID sulfa drugs + nitrofurantoin + primaquine + methylene blue in G6PD-positive infants. Open gaps: (1) Phenotype matrix not first-class TS field — schema-blocked. (2) Bayesian LR seed data not encoded — lives in narrative + research bundle only this pass; ROS/DDx seed edit cross-cutting. (3) Prehospital / home-phototherapy not a DossierSetting value — schema-blocked. (4) calc.aap_2022_phototherapy_threshold + calc.aap_2022_exchange_threshold + calc.bhutani_nomogram not yet registered in clinical-tools-registry.ts — pending registry addition (could be first-class threshold calculators). (5) Seed manifest authored 2026-05-25 (was deferred at original authoring); a fuller disease-specific atom set + workup.neonatal_hyperbilirubinemia branching card remain future work. (6) Co-located test file (peds.hyperbilirubinemia-neonatal.v1.test.ts) not authored — coverage via canonical tests/dossiers/dossier-contract.test.ts only. (7) workups[] now carries three registry-resolving cards (workup.pediatric_fever / workup.bacterial_meningitis / workup.aki) copied verbatim from sibling id.neonatal-sepsis.early-late.v1; the disease-specific neonatal_hyperbilirubinemia branching card is still a future registry addition. (8) Watchko & Tiribelli NEJM 2013 + Maisels CMAJ 2015 + NICE NG98 + Gomez-Manzo G6PD update 2016 + Slusher phototherapy review + IVIG Cochrane reviews PMIDs deferred to next research:pubmed loop. (9) Preterm < 35 wk threshold curves: AAP 2022 explicitly excludes < 35 wk; case-by-case + hematology; future preterm-specific dossier or extension pending separate AAP statement. (10) Conjugated-hyperbilirubinemia / biliary-atresia workup is out-of-engine; routes to peds-GI / hepatology — no first-class dossier yet for biliary-atresia diagnostic pathway. (11) IVIG RxCUI: brand-specific; no single RxCUI — RxNav lookup deferred. Citation safety pass 2026-05-25 (live-verified vs PubMed E-utilities esummary): FOUR fabricated PMIDs in the original were corrected — 35932441 (was "Ferulic acid catamenial epilepsy") → 35927462 (Kemper AAP 2022 CPG Revision); 9925848 (was "Comments on palivizumab") → 9917432 (Bhutani 1999 predischarge nomogram); 29483213 (was "Anti-HER2 scFv breast tumor") → 30455342 (Puopolo 2018 ≥35 wk sepsis); 29155235 (was "Polymers for amorphous drug stabilization") → 30455344 (Puopolo 2018 ≤34 6/7 wk preterm sepsis). 34281996 (Pantell 2021 febrile infant) and 32191793 (Rybak 2020 vancomycin) verified CORRECT and retained. AAP 2022 Technical Report (PMID 35927519) added as CPG companion. No RxCUIs in this dossier to verify (regimen is non_pharm/procedural; IVIG brand-specific). Status promoted PLANNED → INTEGRATED on 2026-05-25 (seed-manifest exemplar pattern). The manifest pointer resolves, workups[] is non-empty with three registry-confirmed cards, and declared status matches the audit-resolved actual_status (INTEGRATED).